Annexon (ANNX) Amortization of Deferred Charges (2021 - 2026)

Annexon's (ANNX) quarterly Amortization of Deferred Charges came in at $418000.0 in Q1 2026, up 16.43% year-on-year from $359000.0 in Q1 2025, and up 3.98% quarter-over-quarter from $402000.0 in Q4 2025.

Annexon (ANNX) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends

Annexon's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $418000.0 for Q1 2026.

  • On a quarterly basis, Amortization of Deferred Charges rose 16.43% year-over-year to $418000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 16.53% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 16.56% from the prior year.
  • Amortization of Deferred Charges climbed to $418000.0 in Q1 2026 per ANNX's latest filing, from $402000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $488000.0 in Q4 2022 and bottomed at $230000.0 in Q1 2022.
  • The 5-year median for Amortization of Deferred Charges is $319000.0 (2024), against an average of $327411.8.
  • Biggest YoY gain for Amortization of Deferred Charges was 69.12% in 2022; the steepest drop was 40.38% in 2022.
  • Year by year, Amortization of Deferred Charges stood at $488000.0 in 2022, then sank by 39.34% to $296000.0 in 2023, then rose by 16.55% to $345000.0 in 2024, then increased by 16.52% to $402000.0 in 2025, then gained by 3.98% to $418000.0 in 2026.
  • Per Business Quant, the three latest ANNX Amortization of Deferred Charges figures stand at $418000.0 (Q1 2026), $402000.0 (Q4 2025), and $387000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn -
2 Nanobiotix 1,905.61 Bn 1,905.55 Bn -
3 Akari Therapeutics 1,011.81 Bn 1,011.81 Bn -
4 BeOne Medicines 467.29 Bn 462.50 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.89 Bn 115.65 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.28 Bn 61.53 Bn 3.31 Bn
7 Belite Bio 62.93 Bn 62.93 Bn -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.64 Bn 34.63 Bn 959.66 Mn
10 Annexon 1.02 Bn 1.02 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 418,000.00
Mar 31, 2026 418,000.00
Dec 31, 2025 402,000.00
Dec 31, 2025 402,000.00
Sep 30, 2025 387,000.00
Sep 30, 2025 387,000.00
Jun 30, 2025 372,000.00
Jun 30, 2025 372,000.00
Mar 31, 2025 359,000.00
Mar 31, 2025 359,000.00
Dec 31, 2024 345,000.00
Dec 31, 2024 345,000.00
Sep 30, 2024 332,000.00
Sep 30, 2024 332,000.00
Jun 30, 2024 319,000.00
Jun 30, 2024 319,000.00
Mar 31, 2024 308,000.00
Mar 31, 2024 308,000.00
Dec 31, 2023 296,000.00
Dec 31, 2023 296,000.00